Charcot Marie Tooth Disease (CMT)

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

VP
Vanda PharmaceuticalsWASHINGTON, DC
1 program
1
VCA-894APhase 1/21 trial
Active Trials
NCT07223632Active Not Recruiting1Est. Mar 2026

Trial Timeline

Clinical trial activity over time

2025
2026
Vanda PharmaceuticalsVCA-894A

Clinical Trials (1)

Total enrollment: 1 patients across 1 trials

Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient

Start: May 2025Est. completion: Mar 20261 patients
Phase 1/2Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space